{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 461094948
| IUPAC_name = 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9''H'',15''H''-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4''H'')-one
| image = Eribulin.svg
| width = 300

<!--Clinical data-->
| tradename = Halaven
| Drugs.com = {{drugs.com|CDI|eribulin}}
| MedlinePlus = a611007
| licence_EU = <!-- EMEA requires brand name -->
| licence_US = Eribulin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = D
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = 静脉注射

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|SciFinder}}
| CAS_number = 253128-41-5
| ATC_prefix = L01
| ATC_suffix = XX41
| ATC_supplemental =  
| PubChem = 17755248
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21396142
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LR24G6354G
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1237028

<!--Chemical data-->
| chemical_formula =  
| C=40 | H=59 | N=1 | O=11 
| molecular_weight = 729.90 g/mol
| smiles = NC[C@@H](O)C[C@H]5O[C@H]4C[C@H]9O[C@@H](CC[C@@H]1O[C@H](CC1=C)CC[C@@]32O[C@@H]6[C@@H]8O[C@H](C2)[C@H](O3)[C@@H]8O[C@H]7CC[C@H](CC(=O)O[C@@H]4[C@H]5OC)O[C@H]67)C[C@@H](C)C9=C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C39H57NO12/c1-18-11-22-5-7-25-19(2)12-24(44-25)9-10-39-16-30-35(51-39)36-37(49-30)38(52-39)33-26(48-36)8-6-23(46-33)14-31(42)50-34-29(15-27(45-22)20(18)3)47-28(32(34)43-4)13-21(41)17-40/h18,21-30,32-38,41H,2-3,5-17,40H2,1,4H3/t18-,21+,22+,23-,24+,25+,26+,27-,28-,29+,30-,32+,33+,34+,35+,36+,37-,38+,39+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VEPHOPLDBFLPDL-KVWSPMLQSA-N
}}
'''艾日布林（{{lang-en|Eribulin}}）''' 是一种[[化疗药物|化疗药物]]，由'''衛采'''[[卫材制药|制药]]研发。其被批准用来治疗[[乳腺癌|乳腺癌]]和[[脂肪肉瘤|脂肪肉瘤]]。

==批准和适应证==
===乳腺癌===
[[甲磺酸|甲磺酸]]盐形式的艾日布林被美国[[食品药品监督管理局|食品药品监督管理局]](FDA)于2010年11月15日批准用于治疗已接受至少两套[[化疗|化疗]]方案的[[远端转移|转移]][[乳腺癌|乳腺癌]]。<ref>{{cite press release | title = FDA approves new treatment option for late-stage breast cancer | publisher = USFDA | date = 2010-11-15 | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm233863.htm | accessdate = November 15, 2010}}</ref>

===脂肪肉瘤===
2016年1月美国FDA批准艾日布林用于治疗无法[[手术|手术]]并已接受过包括[[蒽环类药物|蒽环类药物]]在内的化疗方案的脂肪肉瘤。<ref name=FDA-lipo2016>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483714.htm FDA approves first drug to show survival benefit in liposarcoma. Jan 2016]</ref> 一项三期临床试验报告指出，接受艾日布林治疗患者的中位数总存活率为15.6月，而使用达卡巴嗪治疗的患者则为8.4个月。比使用达卡巴嗪治疗的患者高。<ref name=FDA-lipo2016/>

==引用==
{{reflist}}
{{化疗药物}}
[[Category:抗肿瘤药|Category:抗肿瘤药]]
[[Category:大环化合物|Category:大环化合物]]
[[Category:四氢呋喃|Category:四氢呋喃]]
[[Category:四氢吡喃|Category:四氢吡喃]]